Scientists report advantage of Eli Lilly bone drug over rival

Eli Lilly's treatment Forteo improved spine and hip bone density more effectively than Merck & Co.'s Fosamax, according to a study of 428 patients with osteoporosis. Forteo enhanced the bone density of the lumbar spine by 7.2% compared to 3.4% for Fosamax recipients, and also increased hip bone density by 3.8% compared to 2.4% for patients using Merck's candidate, researchers in Alabama found.

View Full Article in:

Indianapolis Star (tiered subscription model), The · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX